Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Lucie AmoureuxCatherine Neuwirth

Abstract

Achromobacter spp. are emerging pathogens in Cystic Fibrosis (CF) patients. Recent studies proposed Multilocus Sequence Typing (MLST) scheme and a species-level identification method by nrdA sequencing for this genus. Epidemiological data are needed to assess the species and/or the sequence types (STs) involved and their potential role in CF patients lung function degradation. The aims of this study were i) to describe the distribution of the different species of Achromobacter in our CF centre ii) to detect potential STs more involved in chronic colonisations iii) to detect a potential local or worldwide predominance of some STs among clinical and environmental isolates. All the isolates (477) collected in our CF centre from 2007 to 2014 among the 177 patients attending the centre were identified using nrdA sequencing. MLST analysis was performed for 37 clinical and 14 environmental isolates. A total of 47 out of 177 patients presented positive culture(s) with Achromobacter spp., representing 12.7% of the patients of the centre each year. Eleven species were detected, A. xylosoxidans being the most prevalent species (27 patients). Only A. xylosoxidans (>80%) and A. insuavis were involved in chronic colonisation (6.7%). MLST ana...Continue Reading

References

Mar 26, 2008·Antimicrobial Agents and Chemotherapy·Yohei DoiPatrice Nordmann
Dec 15, 2010·BMC Bioinformatics·Keith A Jolley, Martin C J Maiden
Feb 1, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A LambiaseV Raia
Aug 13, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Winnie RidderbergNiels Nørskov-Lauritsen
Aug 19, 2011·Journal of Clinical Microbiology·Rosana H V PereiraElizabeth A Marques
Sep 5, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Lucie AmoureuxCatherine Neuwirth
Oct 24, 2012·Antimicrobial Agents and Chemotherapy·Julien BadorCatherine Neuwirth
Nov 13, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Theodore SpilkerJohn J Lipuma
Jan 30, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Marcos Pérez-LosadaKeith A Crandall
Jun 5, 2014·Current Microbiology·German TragliaMaría Soledad Ramírez
Mar 21, 2015·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Chloé DupontHélène Marchandin
Sep 29, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Amy CowardJane F Turton

❮ Previous
Next ❯

Citations

Aug 11, 2018·Current Opinion in Pulmonary Medicine·Heather Green, Andrew M Jones
Aug 21, 2020·Antimicrobial Agents and Chemotherapy·Burcu IslerDavid L Paterson
Mar 11, 2021·MBio·Marija DmitrijevaChristian von Mering
Apr 14, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T GarrigosUNKNOWN Collaborators
May 21, 2019·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Lucie AmoureuxUNKNOWN MucoMicrobes group
Aug 8, 2021·International Journal of Molecular Sciences·Fernando Sanz-GarcíaSara Hernando-Amado

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

© 2022 Meta ULC. All rights reserved